Skip to main content

Market Overview

Recap: Immunogen Q4 Earnings

Share:

Shares of Immunogen (NASDAQ:IMGN) moved higher by 2.9% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 433.33% year over year to $0.16, which beat the estimate of ($0.08).

Revenue of $85,798,000 up by 91.24% year over year, which beat the estimate of $40,830,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $65,000,000 and $75,000,000.

Details Of The Call

Date: Feb 12, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kk8uk2b5

Technicals

Company's 52-week high was at $8.33

Company's 52-week low was at $1.95

Price action over last quarter: Up 33.82%

Company Profile

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

 

Related Articles (IMGN)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com